- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Arvinas Inc (ARVN)
Track today's live Arvinas (ARVN) share price, performance and key data on this page with our current NASDAQ:ARVN stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Arvinas share price on the NASDAQ exchange. Use the dropdown to switch exchange for the ARVN share price, head to our technical summary section, which provides analysis on Arvinas share price buy/sell indicators using real-time data (or discuss the Arvinas (ARVN) stock price today with other investors in the Arvinas NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:ARVN share price (ISIN: US04335A1051) to enhance your trading decisions with our free investment tools and resources.
What Is the Arvinas Inc Share Price Today?
The Arvinas share price today is 8.69.
What Is the Stock Symbol for Arvinas Inc
The stock symbol (or 'ticker') for Arvinas Inc is "ARVN."
What Stock Exchange Does Arvinas Inc Trade On?
Arvinas Inc is listed and trades on the NASDAQ stock exchange.
Is Arvinas Inc a Good Stock to Buy?
Determining whether Arvinas (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:ARVN share price (ISIN: US04335A1051) to enhance your trading decisions with our free investment tools and resources.
What Is the Arvinas Inc Share Price Today?
The Arvinas share price today is 8.69.
What Is the Stock Symbol for Arvinas Inc
The stock symbol (or 'ticker') for Arvinas Inc is "ARVN."
What Stock Exchange Does Arvinas Inc Trade On?
Arvinas Inc is listed and trades on the NASDAQ stock exchange.
Is Arvinas Inc a Good Stock to Buy?
Determining whether Arvinas (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.37
8.72
52 wk Range
6.06
14.51
Unusual trading volume
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.378.72
52 wk Range
6.0614.51
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ARVN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
14.57
Upside
+67.68%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Holds more cash than debt on its balance sheet
- Arvinas Holding receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Why is Arvinas stock surging today?- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
7 Buy
8 Hold
1 Sell
Ratings:
16 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 14.57
(+67.68% Upside)
Arvinas Inc SWOT Analysis
Vepdegestrant's Promise | Explore vepdegestrant's potential as a first-in-class oral PROTAC for ESR1-mutant breast cancer patients, with promising efficacy in recent trials |
Financial Crossroads | Delve into Arvinas's strategic restructuring and financial outlook, balancing cost-cutting measures with a healthy cash position and extended runway |
Market Dynamics | Learn about the challenges Arvinas faces in the competitive oral SERD market, with analyst price targets ranging from $10 to $48 |
Platform Potential | Discover the broader implications of Arvinas's PROTAC platform technology, offering opportunities beyond vepdegestrant in addressing "undruggable" proteins |
Arvinas Inc Earnings Call Summary for Q2/2026
- Arvinas posted Q2 EPS of $2.58 vs. expected loss of $0.38; revenue hit $249.7M vs. forecast $58.6M, driven by licensing and Pfizer accounting changes.
- Company reported $567.9M in cash at quarter-end, sufficient to fund operations into H2 2028; R&D expenses fell 23.3% YoY to $52.6M.
- Revenue surge attributed to $62.5M Rigel license, $126.4M Pfizer deferred revenue recognition, and $50M VEPPANU FDA approval milestone.
- Key pipeline catalysts include ARV-393 Phase I data by end-2026, ARV-027 data H1 2027, and ARV-6723 Phase I trial starting in coming weeks.
- CEO highlighted FDA approval of first PROTAC degrader VEPPANU and out-licensing to Rigel as strategic milestones; shares rose 2.11% premarket to $8.23.
Last Updated: 04/08/2026, 14:08
Read Full TranscriptEarnings
Latest Release
04/08/2026
EPS / Forecast
2.58 / -0.38
Revenue / Forecast
249.7M / 58.61M
Compare ARVN to Peers and Sector
Metrics to compare | ARVN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipARVNPeersSector | |
|---|---|---|---|---|
P/E Ratio | 61.1x | −9.9x | −0.4x | |
PEG Ratio | 0.53 | 0.02 | 0.00 | |
Price/Book | 1.0x | 3.2x | 2.6x | |
Price / LTM Sales | 1.8x | 32.2x | 3.0x | |
Upside (Analyst Target) | 63.9% | 48.0% | 51.8% | |
Fair Value Upside | Unlock | −5.8% | 7.2% | Unlock |
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Arvinas (NASDAQ: ARVN) Share Price Today?
The Arvinas stock price today is 8.69 USD.
What Stock Exchange Does Arvinas (ARVN) Trade On?
Arvinas is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Arvinas?
The stock symbol (also called a 'ticker') for Arvinas is "ARVN."
What Is the Current Arvinas Market Capitalisation?
As of today, Arvinas (NASDAQ: ARVN) market cap is 549.24M USD.
What Is Arvinas's (ARVN) Earnings Per Share (TTM)?
The Arvinas EPS is currently 0.13 (Trailing Twelve Months).
When Is the Next Arvinas Earnings Date?
Arvinas's next earnings report will be released on 10/11/2026.
Is ARVN a Buy or Sell From a Technical Analyst Perspective?
Based on today's Arvinas moving averages and other technical indicators, the daily buy/sell signal for ARVN stock is Strong Buy.
How Many Times Has Arvinas Stock Split?
Arvinas has split 0 times. (See the ARVN stock split history page for full effective split date and price information.)
How Many Employees Does Arvinas Have?
Arvinas has 246 employees, based on their latest Companies House report.
What is the current trading status of Arvinas (NASDAQ: ARVN)?
As of 07/08/2026, Arvinas (ARVN) is trading at a share price of 8.69 USD, with a previous close of 8.40 USD. The stock has fluctuated within a day range of 8.37 USD to 8.72 USD, while its 52-week range spans from 6.06 USD to 14.51 USD.
What Is Arvinas (ARVN) Price Target According to Analysts?
The average 12-month price target for Arvinas is 14.57 USD, with a high estimate of 24 USD and a low estimate of 6 USD. 7 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +67.68% Upside potential.
What Is the ARVN Premarket Price?
ARVN's last pre-market stock price is 8.50 USD. The pre-market share volume is 2,240.00, and the stock has decreased by 0.10, or 1.19%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.